Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD - Würselen, Germany

ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.

Video navigation menu

CV risk in CKD - the magnitude of the problem 00:33
CV risk factors in CKD and effect of standard CV therapy 03:47
Vascular calcification in CKD is an active process 05:56
Epigenetic changes in CKD and interfering with a BET-inhibitor 07:23
Human evidenct of BET-inhibition: the BETonMACE trial 10:36

Educational information

This lecture by prof. Vincent Brandenburg was part of a CME accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.

Faculty

Vincent Brandenburg, MD is head of the Division of Nephrology at the Rhein-Maas Klinikum in Würselen, Germany.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.